

# CITATION REPORT

List of articles citing

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter

DOI: 10.1016/j.cjca.2010.11.007

Canadian Journal of Cardiology, 2011, 27, 74-90.

**Source:** <https://exaly.com/paper-pdf/50242126/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
255	The role of aspirin for stroke prevention in atrial fibrillation. <b>2011</b> , 8, 602-6		81
254	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. <b>2011</b> , 105, 908-19		154
253	New Insights into Anticoagulation in Atrial Fibrillation. <b>2011</b> , 27, 186-192		
252	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 47-59	3.8	84
251	From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 19-26	3.8	38
250	It's health care delivery, stupid: implementing the New Canadian Cardiovascular Society atrial fibrillation treatment guidelines. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 14-8	3.8	4
249	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: surgical therapy. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 67-73	3.8	15
248	Comparing the 2010 North American and European atrial fibrillation guidelines. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 7-13	3.8	19
247	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 38-46	3.8	88
246	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 31-7	3.8	54
245	A proud tradition and a new beginning with a theme issue on atrial fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 5-6	3.8	
244	In-hospital management of atrial fibrillation: the CHADS <sub>2</sub> score predicts increased cost. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 506-13	3.8	15
243	"Show me the money": the cost of atrial fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 401-3	3.8	
242	Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease. <b>2011</b> , 306, 2367-74		17
241	DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER. <b>2011</b> , 7, 757-764		
240	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. <b>2012</b> , 7, 1-13		3
239	A Systematic Approach to Stroke Prevention for Patients with Atrial Fibrillation. <b>2011</b> , 144, 287-294		1

238	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <b>2011</b> , 106, 997-1011		184
237	New anticoagulants for atrial fibrillation: the beginning of a new era in stroke prevention. <b>2011</b> , 38, 777-82		
236	Urgent statement on antithrombotic therapy of atrial fibrillation. <b>2011</b> , 75, 2719-21		17
235	Bleeding risk in real world patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. <b>2011</b> , 9, 1460-7		151
234	Bleeding risk with oral anticoagulation--new frontiers and new questions. <b>2011</b> , 65, 719-21		
233	Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. <b>2011</b> , 9 Suppl 1, 344-51		67
232	Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. <b>2011</b> , 31, 1208-20		8
231	Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. <b>2011</b> , 10, 84-6		
230	A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. <i>Stroke</i> , <b>2011</b> , 42, 3316-22	6.7	24
229	Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. <b>2011</b> , 13, 1368-74		22
228	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <b>2011</b> , 13, 723-46		166
227	Update on the clinical management of atrial fibrillation: guidelines and beyond. <b>2011</b> , 123, 7-20		6
226	The older patient with heart failure: high risk for frailty and cognitive impairment. <b>2012</b> , 10, 779-95		25
225	Current issues in atrial fibrillation. <b>2012</b> , 2012, 376071		
224	Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?. <b>2012</b> , 5, 459-66		53
223	Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. <b>2012</b> , 5, 1168-75		11
222	Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. <b>2012</b> , 5, 941-8		58
221	Current world literature. <b>2012</b> , 25, 96-102		

220	Stroke prevention in atrial fibrillation: do we still need warfarin?. <b>2012</b> , 25, 27-35		8
219	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. <b>2012</b> , 27, 331-9		9
218	Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. <b>2012</b> , 19, 4688-98		5
217	Risk of bleeding related to antithrombotic treatment in cardiovascular disease. <b>2012</b> , 18, 5362-78		5
216	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. <i>Heart</i> , <b>2012</b> , 98, 573-8	5.1	91
215	Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. <b>2012</b> , 5, 319-26		85
214	Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. <b>2012</b> , 5, 312-8		93
213	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <b>2012</b> , 6, 65-78		8
212	Letter by Nammias regarding article, "Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?". <b>2012</b> , 5, e88		
211	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. <b>2012</b> , 125, 1577-83		16
210	Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. <i>Stroke</i> , <b>2012</b> , 43, 1179-85	6.7	7
209	A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. <b>2012</b> , 33, 2163-71		43
208	Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. <b>2012</b> , 14, 312-24		27
207	Atrial fibrillation in heart failure: an innocent bystander?. <b>2012</b> , 8, 273-80		5
206	Stroke prevention in atrial fibrillation: concepts and controversies. <b>2012</b> , 8, 290-301		8
205	Atrial fibrillation in acute ST-elevation myocardial infarction: clinical and prognostic features. <b>2012</b> , 8, 281-9		17
204	Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group on Hypertension Arrhythmias and Thrombosis of the European Society of Hypertension. <b>2012</b> , 30, 239-52		138
203	Sleep apnea and atrial fibrillation; 2012 update. <b>2012</b> , 8, 265-72		48

202	Atrial fibrillation. <b>2012</b> , 379, 648-61		287
201	New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. <b>2012</b> , 13, 2649-61		8
200	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <b>2012</b> , 380, 1749-58		150
199	Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants. <b>2012</b> , 26, 331-8		7
198	New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. <b>2012</b> , 65, 7-13		
197	[Dabigatran: beyond the RE-LY study]. <b>2012</b> , 212 Suppl 2, 1-3		
196	[Scope of the latest RE-LY substudies: clinical implications]. <b>2012</b> , 212 Suppl 2, 4-14		
195	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <b>2012</b> , 14, 1385-413		1019
194	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. <i>Più luci che ombre</i> . <b>2012</b> , 6, 153-169		
193	New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. <b>2012</b> , 65, 7-13		23
192	[Progress in cardiac electrophysiology and arrhythmias]. <b>2012</b> , 65 Suppl 1, 73-81		2
191	Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 125-36	3.8	389
190	Stroke prevention in atrial fibrillation: latest clinical trials and guidelines. <b>2012</b> , 5, 384-97		2
189	The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. <b>2012</b> , 142, 1489-1498		281
188	Anticoagulation therapy. Dabigatran and risk of myocardial infarction. <b>2012</b> , 9, 260-2		23
187	[Atrial fibrillation: from cardiology to perioperative management]. <b>2012</b> , 31, 897-910		5
186	Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region. <b>2012</b> , 28, 41-55		3
185	Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. <b>2012</b> , 172, 1537-45		52

184	Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. <b>2012</b> , 172, 623-31; discussion 631-3		120
183	Personalized cardiovascular medicine: status in 2012. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 693-9	3.8	8
182	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <b>2012</b> , 33, 2719-47		2638
181	Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. <b>2012</b> , 2012, 108983		10
180	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. <b>2012</b> ,		
179	Dabigatran in atrial fibrillation: New kid on the block. <b>2012</b> , 145, 83-87.e1		2
178	New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. <b>2012</b> , 8, 45-57		10
177	Warfarin versus dabigatran: comparing the old with the new. <b>2012</b> , 27, 121-4		3
176	Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. <b>2012</b> , 107, 51-8		10
175	Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. <b>2012</b> , 125, 2298-307		337
174	The CHADS <sub>2</sub> versus the new CHA <sub>2</sub> DS <sub>2</sub> -VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. <b>2012</b> , 32, 285-96		34
173	Can we predict stroke in atrial fibrillation?. <b>2012</b> , 35 Suppl 1, 21-7		25
172	Emergency management of bleeding associated with old and new oral anticoagulants. <b>2012</b> , 35, 730-7		47
171	Anticoagulant therapy for patients with ischaemic stroke. <b>2012</b> , 8, 319-28		25
170	The value of the CHA <sub>2</sub> DS <sub>2</sub> -VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS <sub>2</sub> score 0-1: a nationwide cohort study. <b>2012</b> , 107, 1172-9		326
169	Novel anticoagulants for atrial fibrillation: a critical appraisal. <b>2012</b> , 63, 164-70		13
168	[New anticoagulants for stroke prevention in atrial fibrillation]. <b>2012</b> , 37, 370-7		3
167	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. <b>2012</b> , 271, 15-24		39

166	An earnest search for atrial fibrillation patients without thromboembolic risk. <b>2012</b> , 23, 714-6		
165	Atrial fibrillation registries, administrative databases, clinical trials, and outcomes. <b>2012</b> , 109, 443-4		
164	Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. <b>2012</b> , 34, 766-87		15
163	Prevention of stroke in atrial fibrillation: cautious optimism. <b>2012</b> , 11, 203-5		1
162	Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. <b>2013</b> , 11, 1647-54		26
161	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <b>2013</b> , 62, 1495-1539		233
160	Genetics of coagulation: what the cardiologist needs to know. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 75-88	3.8	4
159	Management of cardiovascular disease in patients with kidney disease. <b>2013</b> , 10, 261-73		74
158	Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. <b>2013</b> , 11, 1485-92		30
157	Management of atrial fibrillation in the year 2033: new concepts, tools, and applications leading to personalized medicine. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1141-6	3.8	27
156	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <b>2013</b> , 128, e240-327		1927
155	Missed opportunities for appropriate anticoagulation among emergency department patients with uncomplicated atrial fibrillation or flutter. <b>2013</b> , 62, 557-565.e2		31
154	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. <b>2013</b> , 34, 1471-4		51
153	Anticoagulation in Patients Aged ≥5 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. <b>2013</b> , 2, 135-49		28
152	Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 204-12	3.8	41
151	Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). <b>2013</b> , 15, 135-40		66
150	CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. <b>2013</b> , 102, 139-44		29
149	Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. <b>2013</b> , 27, 23-35		24

148	The evolving role of stroke prediction schemes for patients with atrial fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1173-80	3.8	7
147	Anticoagulation management pre- and post atrial fibrillation ablation: a survey of canadian centres. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 219-23	3.8	31
146	Percutaneous closure of the left atrial appendage for thromboembolic prevention in atrial fibrillation. <b>2013</b> , 32, 311-323		
145	Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: a single-center experience. <b>2013</b> , 32, 461-71		11
144	Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. <b>2013</b> , 66, 545-52		17
143	Mise à jour des recommandations européennes et comparaison avec les recommandations nord-américaines. <b>2013</b> , 5, 161-167		
142	Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: A single-center experience. <b>2013</b> , 32, 461-471		5
141	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012: Actualización de las guías de la Sociedad Europea de Cardiología (ESC) para el manejo de la fibrilación auricular de 2010 Elaborada en colaboración con la Asociación Europea del Ritmo Cardíaco. <b>2013</b> , 66, 545-1-54-e24		10
140	Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes. Estudio AFABE. <b>2013</b> , 66, 545-552		51
139	Percutaneous closure of the left atrial appendage for thromboembolic prevention in atrial fibrillation. <b>2013</b> , 32, 311-23		2
138	Anticoagulation for atrial fibrillation: state of the art and recommendations for a quickly moving target. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, S1-3	3.8	
137	The APHRSQ 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. <b>2013</b> , 29, 190-200		60
136	Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1110-7	3.8	11
135	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. <b>2013</b> , 11, 129-41		29
134	Managing anticoagulation for atrial fibrillation: current issues and future strategies. <b>2013</b> , 273, 31-41		7
133	Review of epidemiology and management of atrial fibrillation in developing countries. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2412-20	3.2	82
132	Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 224-8	3.8	64
131	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2013</b> , 62, e147-239		43 <sup>18</sup>



130	Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, S60-70	3.8	9
129	Practice implications of the Atrial Fibrillation Guidelines. <b>2013</b> , 111, 1660-70		10
128	Stroke Stop Study: Editorial comment. <b>2013</b> , 15, 5-6		4
127	Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. <b>2013</b> , 1, E115-9		59
126	2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <b>2013</b> , 128, 1810-52		2321
125	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <b>2013</b> , 11, 77-90		7
124	Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. <b>2013</b> , 91, 20-4		3
123	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. <b>2013</b> , 34, 1041-9		108
122	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly. <b>2013</b> , 77, 1380-8		31
121	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <b>2013</b> , 110, 1087-107		278
120	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. <b>2013</b> , 110, 560-8		31
119	Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. <i>PLoS ONE</i> , <b>2013</b> , 8, e63479	3.7	297
118	Management of stroke prevention in canadian patients with atrial fibrillation at moderate to high risk of stroke. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2013</b> , 66, 296-303	0.5	1
117	Hemostatic Aspects of Cardiovascular Medicine. <b>2013</b> , 342-394		
116	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. <b>2013</b> , 7, 8		2
115	Can dynamic contour tonometry and ocular pulse amplitude help to detect severe cardiovascular pathologies?. <b>2014</b> , 8, 1317-21		9
114	Stroke prevention in patients with atrial fibrillation and renal dysfunction. <i>Stroke</i> , <b>2014</b> , 45, 2497-505	6.7	12
113	Prevention of Stroke in Patients With Atrial Fibrillation. <b>2014</b> , 1129-1137		

112	Cardioembolic stroke: practical considerations for patient risk management and secondary prevention. <b>2014</b> , 126, 55-65			8
111	Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. <b>2014</b> , 161, 690-8			58
110	Anticoagulant Treatment. <b>2014</b> , 214-218			
109	An explanation of recommendation differences: illustrations from recent atrial fibrillation guidelines. <b>2014</b> , 37, 116-27			4
108	Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1541-6	3.8		22
107	Evaluation and care of a patient with new-onset atrial fibrillation. <i>Cmaj</i> , <b>2014</b> , 186, 204-5	3.5		2
106	Increased risk of myocardial infarction with dabigatran: fact or fiction?. <b>2014</b> , 15, 19-26			7
105	Perioperative challenges of atrial fibrillation. <b>2014</b> , 27, 344-52			28
104	Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. <b>2014</b> , 3, e000515			73
103	Current perspectives on cardioembolic ischemic stroke in very old patients. <b>2014</b> , 1			
102	Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1216-24	3.8		48
101	Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks. <b>2014</b> , 20, 5-15			4
100	The antithrombotic effect of dabigatran. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 248.e1-2	3.8		3
99	Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. <b>2014</b> , 78, 707-17			32
98	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. <b>2014</b> , 107, 77-87			68
97	Target-specific oral anticoagulants in patients undergoing cardioversion. <b>2014</b> , 71, 1171-6			2
96	Poststroke atrial fibrillation: cause or consequence? Critical review of current views. <b>2014</b> , 82, 1180-6			70
95	Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials. <b>2014</b> , 12, 1419-24			23

94	Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. <b>2014</b> , 20, 665-72		27
93	Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. <b>2014</b> , 37, 507-23		29
92	Efficacy of N-acetylcysteine in preventing atrial fibrillation after cardiac surgery: a meta-analysis of published randomized controlled trials. <b>2014</b> , 14, 52		20
91	Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. <i>Heart Rhythm</i> , <b>2014</b> , 11, 1752-9	6.7	60
90	Atrial fibrillation therapies: lest we forget surgery. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 590-7	3.8	5
89	[The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study]. <b>2014</b> , 46, 58-67		5
88	Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 231-6	3.8	32
87	The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. <b>2014</b> , 134, 294-9		28
86	Which score should be used for risk stratification of ischemic stroke in patients with atrial fibrillation. <b>2014</b> , 78, 1331-2		3
85	Performance of the "CCS Algorithm" in real world patients. <b>2015</b> , 7, 18-21		
84	Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). <b>2015</b> , 21, 736-41		21
83	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. <i>Journal of Cardiovascular Pharmacology</i> , <b>2015</b> , 66, 530-9	3.1	1
82	Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124806	3.7	19
81	Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. <b>2015</b> , 5, e009518		6
80	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <b>2015</b> , 36, 653-6		41
79	The new Canadian Cardiovascular Society algorithm for antithrombotic therapy of atrial fibrillation is appropriately based on current epidemiologic data. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 20-3	3.8	7
78	One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation: A Prospective, Multicenter Registry in China. <b>2015</b> , 66, 745-52		8
77	Managing atrial fibrillation. <b>2015</b> , 65, 532-9		15

76	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , <b>2015</b> , 101, 1446-55	5.1	41
75	Pharmacists' Role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies. <b>2015</b> , 37, 656-68		7
74	Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. <i>Medicine (United States)</i> , <b>2015</b> , 94, e377	1.8	12
73	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. <b>2015</b> , 37, 2506-2514.e4		106
72	The Disconnect Between Novel Oral Anticoagulant Eligibility and Provincial Drug Coverage: An Albertan Anticoagulation Clinic Audit. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1047-50	3.8	4
71	Safety of urgent cardioversion for patients with recent-onset atrial fibrillation and flutter. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 239-41	3.8	7
70	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <b>2016</b> , 31, 541-61		15
69	Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <b>2016</b> , 18, D1-D6		6
68	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. <b>2016</b> , 179, 186-91		5
67	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1170-1185	3.8	212
66	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. <b>2016</b> , 151, 1105-1112.e10		48
65	Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke. <b>2016</b> , 128, 620-8		3
64	Learning to Make Decisions: Are Medical Postgraduate Trainees Getting With the Atrial Fibrillation Guidelines?. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 714-6	3.8	
63	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , <b>2016</b> , 102, 57-62	5.1	30
62	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. <b>2016</b> , 15, 731-40		5
61	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i> , <b>2016</b> , 13, e136-221	6.7	58
60	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <b>2016</b> , 67, e27-e115		246
59	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <b>2016</b> , 133, e506-74		142

58	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 336-43	3.8	11
57	The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 169-76	3.8	86
56	Prevalencia de fibrilaci3n auricular y caracter3sticas de la fibrilaci3n auricular no valvular en la poblaci3n general. <i>Registro AFINVA</i> . <b>2017</b> , 24, 26-33		4
55	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , <b>2017</b> , 103, 307-314	5.1	163
54	Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice. <i>Obstetric Medicine</i> , <b>2017</b> , 10, 74-78	1.5	5
53	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 965-976	3.8	68
52	Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181766	3.7	18
51	Emergency medicine considerations in atrial fibrillation. <i>American Journal of Emergency Medicine</i> , <b>2018</b> , 36, 1070-1078	2.9	10
50	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 383-390	2.6	1
49	Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. <i>Heart Rhythm</i> , <b>2018</b> , 15, 9-16	6.7	23
48	Anticoagulant Use and Risk of Ischemic Stroke and Bleeding in Patients With Secondary Atrial Fibrillation Associated With Acute Coronary Syndromes, Acute Pulmonary Disease, or Sepsis. <i>JACC: Clinical Electrophysiology</i> , <b>2018</b> , 4, 386-393	4.6	24
47	Evaluation of the predictive performance of bleeding risk scores in patients with non-valvular atrial fibrillation on oral anticoagulants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 209-219	2.2	3
46	[Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?]. <i>Semergen</i> , <b>2018</b> , 44, 297-303	1.9	0
45	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1371-1392	3.8	144
44	The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1412-1425	3.8	7
43	Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies. <i>International Journal of Cardiology</i> , <b>2018</b> , 267, 1-7	3.2	21
42	A Multicenter Randomized Trial to Evaluate a Chemical-first or Electrical-first Cardioversion Strategy for Patients With Uncomplicated Acute Atrial Fibrillation. <i>Academic Emergency Medicine</i> , <b>2019</b> , 26, 969-981	3.4	11
41	New Oral Anticoagulants: An Update. <i>Journal of Bangladesh College of Physicians &amp; Surgeons</i> , <b>2019</b> , 37, 135-150	0.8	

40	Anticoagulation in atrial fibrillation and cognitive decline: A systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2019</b> , 98, e14499	1.8	8
39	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 160-168	3.8	3
38	Active management of atrial fibrillation or flutter in emergency department patients with renal impairment is associated with a higher risk of adverse events and treatment failure. <i>Canadian Journal of Emergency Medicine</i> , <b>2019</b> , 21, 352-360	0.6	1
37	For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2019</b> , 72,	0.5	
36	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e679-e703	1	3
35	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. <i>BMJ Quality and Safety</i> , <b>2019</b> , 28, 835-842	5.4	6
34	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. <i>Cmaj</i> , <b>2019</b> , 191, E1345-E1354	3.5	9
33	Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , <b>2020</b> , 27, e270-e285	1	2
32	Effect of Heart Rate on Stroke Recurrence and Mortality in Acute Ischemic Stroke With Atrial Fibrillation. <i>Stroke</i> , <b>2020</b> , 51, 162-169	6.7	13
31	Risk stratification of patients with atrial fibrillation in the emergency department. <i>American Journal of Emergency Medicine</i> , <b>2020</b> , 38, 1807-1815	2.9	2
30	The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward. <i>Canadian Journal of Cardiology</i> , <b>2020</b> , 36, 1839-1842	3.8	4
29	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2020</b> , 36, 1847-1948	3.8	82
28	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 247-253	4.5	2
27	Poincaré Plot Image and Rhythm-Specific Atlas for Atrial Bigeminy and Atrial Fibrillation Detection. <i>IEEE Journal of Biomedical and Health Informatics</i> , <b>2021</b> , 25, 1093-1100	7.2	4
26	The Trend Is Your Friend: Direct Oral Antagonists as Standard Anticoagulants for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Interventions. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 77, 162-163	3.1	
25	Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160713	3.7	3
24	[Advances in the prevention, diagnosis and therapy of vascular diseases]. <i>Orvosi Hetilap</i> , <b>2012</b> , 153, 483-488	2.8	3
23	Atrial fibrillation in heart failure: The sword of Damocles revisited. <i>World Journal of Cardiology</i> , <b>2013</b> , 5, 215-27	2.1	17

22	Efficacy and Safety of Warfarin Experience in a Stroke Polyclinic in Stroke Patients. <i>Noropsikiyatri Arsvi</i> , <b>2017</b> , 54, 318-321	0.6	1
21	Prevention of thromboembolic complications of atrial fibrillation: Current aspects and perspective. <i>Srce I Krvni Sudovi</i> , <b>2012</b> , 31, 68-76		0
20	Guidelines for perioperative antithrombotic therapy in hair restoration surgery: management of patients with coronary heart disease, mechanical heart valve, and atrial fibrillation. <i>International Society of Hair Restoration Surgery</i> , <b>2012</b> , 22, 59-64	0.2	3
19	Treatment recommendations and guidelines. <b>2012</b> , 30-40		
18	Assessment of the adherence of cardiologists to guidelines for the treatment of atrial fibrillation. <i>Arquivos Brasileiros De Cardiologia</i> , <b>2013</b> , 101, 127-33	1.2	7
17	Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic. <i>Arrhythmia and Electrophysiology Review</i> , <b>2013</b> , 2, 8-15	3.2	
16	Cardiac Arrhythmias. <b>2013</b> , 67-80		
15	Atrial Fibrillation: Should Cardiac Surgeons Be Consulted?. <b>2014</b> , 439-449		
14	Tachycardia-bradycardia syndrome in a patient with atrial fibrillation: a case report. <i>Korean Journal of Anesthesiology</i> , <b>2015</b> , 68, 415-9	3.8	1
13	Naujojo antikoagulianto dabigatranu daugumas ir efektyvumas taikant elektrininkardioversiją <i>Health Sciences</i> , <b>2017</b> , 26, 169-172	0	
12	Choosing an Anticoagulant in an Elderly Patient. <b>2017</b> , 19-24		
11	Anticoagulant therapy and components of the metabolic syndrome in patients with atrial fibrillation in real outpatient clinical practice. <i>Meditisinskiy Sovet</i> , <b>2019</b> , 60-63	0.4	1
10	Optimal warfarin management for the prevention of thromboembolic events in patients with atrial fibrillation: a systematic review of the clinical evidence. <i>CADTH Technology Overviews</i> , <b>2012</b> , 2, e2304		1
9	Correlation between CHADS2 score and anticoagulant use in atrial fibrillation: Results of a mini-survey. <i>Experimental and Clinical Cardiology</i> , <b>2013</b> , 18, 101-3		0
8	Warfarin: its highs and lows. <i>Canadian Family Physician</i> , <b>2013</b> , 59, 856-60	0.9	1
7	Atrial fibrillation anticoagulation care in a large urban family medicine practice. <i>Canadian Family Physician</i> , <b>2014</b> , 60, e173-9	0.9	4
6	Stroke Risk Predictor Scoring Systems in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2014</b> , 6, 998	0.8	5
5	The Optimal Treatment For Atrial Fibrillation In Less Developed Countries. <i>Journal of Atrial Fibrillation</i> , <b>2014</b> , 7, 1147	0.8	2

4	Emergency Physician Patterns Related to Anticoagulation of Patients with Recent-Onset Atrial Fibrillation and Flutter. <i>Journal of Atrial Fibrillation</i> , <b>2013</b> , 5, 645	0.8	3
3	For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2019</b> , 72, 464-467	0.5	
2	Effect of variability of central venous pressure values to prevent atrial fibrillation after coronary bypass grafting. <i>Caspian Journal of Internal Medicine</i> , <b>2021</b> , 12, 299-306	1	
1	Reversal of anticoagulation in neurosurgical and neurocritical care settings. <b>2022</b> , 239-266		